Screener
G&A at other companies
Other financials
Where this comes from
Reported directly by Ocular Therapeutix in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Ocular Therapeutix’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 7:28 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-055256
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Cost of product revenue | 1,329 | 1,262 |
| Research and development | 66,213 | 42,857 |
| Selling and marketing | 16,577 | 14,148 |
| General and administrative | 20,006 | 16,348 |
| Total costs and operating expenses | 104,125 | 74,615 |
| Loss from operations | (93,340) | (63,917) |
| Other income (expense): | ||
| Interest income | 6,050 | 3,826 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Ocular Therapeutix's G&A?
- Ocular Therapeutix (OCUL) reported G&A of $20.01M in Q1 2026.
- How has Ocular Therapeutix's G&A changed year-over-year?
- Ocular Therapeutix's G&A increased by 22.4% year-over-year, from $16.35M to $20.01M.
- What is the long-term trend for Ocular Therapeutix's G&A?
- Over 4 years (2021 to 2025), Ocular Therapeutix's G&A has grown at a 19.2% compound annual growth rate (CAGR), from $31.88M to $64.38M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Ocular Therapeutix's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude